Sverige - svenska - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - kolekalciferol; natriumalendronattrihydrat - tablett - 70 mg/5600 ie - natriumalendronattrihydrat 91,36 mg aktiv substans; kolekalciferol 5600 ie aktiv substans; sackaros hjälpämne; butylhydroxitoluen hjälpämne; laktos (vattenfri) hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - kolekalciferol; natriumalendronattrihydrat - tablett - 70 mg/2800 ie - kolekalciferol 70 mikrog aktiv substans; natriumalendronattrihydrat 91,36 mg aktiv substans; laktos (vattenfri) hjälpämne; butylhydroxitoluen hjälpämne; sackaros hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

strides pharma (cyprus) limited - omega-3-syraetylestrar 90 - kapsel, mjuk - 1000 mg - natriumlaurilsulfat hjälpämne; glycerol hjälpämne; omega-3-syraetylestrar 90 1000 mg aktiv substans; propylenglykol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - omega-3-syraetylestrar 90 - kapsel, mjuk - 1000 mg - omega-3-syraetylestrar 90 1000 mg aktiv substans; glycerol hjälpämne; sojalecitin hjälpämne

Europeiska unionen - svenska - EMA (European Medicines Agency)

amarin pharmaceuticals ireland limited - icosapent ethyl - dyslipidemi - lipidmodifierande medel - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - immunförsvaret sera och immunglobuliner, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Europeiska unionen - svenska - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - immunförsvaret sera och immunglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se avsnitt 4. 4 och 5.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. användning av detta vaccin bör ske i enlighet med officiella rekommendationer. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Europeiska unionen - svenska - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vacciner - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.